HUMA - Humacyte, Inc.
IEX Last Trade
5.47
0.050 0.914%
Share volume: 163,226
Last Updated: Fri 27 Dec 2024 08:30:35 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$5.42
0.05
0.92%
Fundamental analysis
13%
Profitability
0%
Dept financing
14%
Liquidity
75%
Performance
11%
Performance
5 Days
13.76%
1 Month
20.23%
3 Months
-5.20%
6 Months
12.55%
1 Year
77.52%
2 Year
156.80%
Key data
Stock price
$5.47
DAY RANGE
$5.14 - $5.64
52 WEEK RANGE
$2.58 - $9.97
52 WEEK CHANGE
$86.27
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Laura E. Niklason
Region: US
Website: humacyte.com
Employees: 150
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: humacyte.com
Employees: 150
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues. Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company was founded in 2004 and is headquartered in Durham, North Carolina.
Recent news